Skip to content

H.R. 7248 · 118th Congress (2023–2025)

FDA Modernization Act 3.0

This bill requires the Food and Drug Administration (FDA) to establish a process that supports nonclinical testing methods for drug development that do not involve the use of animals.

Specifically, the FDA must establish a pathway by which entities may apply to have nonclinical testing methods approved for use in a particular context. Qualifying methods must be intended to replace or reduce animal testing and to either improve the safety and efficacy of nonclinical testing or reduce the time to develop a drug. The FDA must issue its decision within 180 days of receiving an application. The FDA must also prioritize the review of applications for drugs that are developed using an approved nonclinical testing method.

The FDA must annually post a report on its website that summarizes the results of the bill's implementation, including the number of applications received, types of methods that were approved, and the estimated number of animals saved as result of these methods.

Show official title

To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.

Expired in House committee

Derived from the legislative history, not an official disposition.

Latest actionReferred to Health

This bill’s path

This is H.R. 7248’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed House

  3. Passed Senate

  4. Sent to President

  5. Signed into law

  6. Expired

Sponsor
Rep. Earl L. "Buddy" Carter (R-GA-1)
Cosponsors
46 cosponsors

10 original · 36 later

22 R · 24 D

  1. Rep. Vern Buchanan (R-FL-16)· Original · Feb 6, 2024
  2. Rep. Nanette Diaz Barragán (D-CA-44)· Original · Feb 6, 2024
  3. Rep. Dan Crenshaw (R-TX-2)· Original · Feb 6, 2024
  4. Rep. Troy A. Carter (D-LA-2)· Original · Feb 6, 2024
  5. Rep. Rosa L. DeLauro (D-CT-3)· Original · Feb 6, 2024
  6. Rep. Brian K. Fitzpatrick (R-PA-1)· Original · Feb 6, 2024
  7. Rep. Lance Gooden (R-TX-5)· Original · Feb 6, 2024
  8. Rep. Diana Harshbarger (R-TN-1)· Original · Feb 6, 2024
  9. Rep. Troy E. Nehls (R-TX-22)· Original · Feb 6, 2024
  10. Rep. Michael Waltz (R-FL-6)· Original · Feb 6, 2024
  11. Rep. David G. Valadao (R-CA-22)· Later · Feb 13, 2024
  12. Rep. Joe Neguse (D-CO-2)· Later · Feb 14, 2024
  13. Rep. Gus M. Bilirakis (R-FL-12)· Later · Feb 23, 2024
  14. Rep. Donald G. Davis (D-NC-1)· Later · Feb 23, 2024
  15. Rep. Josh Gottheimer (D-NJ-5)· Later · Feb 29, 2024
  16. Rep. Daniel S. Goldman (D-NY-10)· Later · Mar 5, 2024
  17. Del. Eleanor Holmes Norton (D-DC)· Later · Mar 5, 2024
  18. Rep. Deborah K. Ross (D-NC-2)· Later · Mar 11, 2024
  19. Rep. Brittany Pettersen (D-CO-7)· Later · Mar 19, 2024
  20. Rep. Zoe Lofgren (D-CA-18)· Later · Mar 21, 2024
  21. Rep. Dina Titus (D-NV-1)· Later · Mar 22, 2024
  22. Rep. Michael Lawler (R-NY-17)· Later · Mar 29, 2024
  23. Rep. Jay Obernolte (R-CA-23)· Later · Apr 5, 2024
  24. Rep. Rashida Tlaib (D-MI-12)· Later · Apr 17, 2024
  25. Rep. Tim Burchett (R-TN-2)· Later · Apr 19, 2024
  26. Rep. Christopher H. Smith (R-NJ-4)· Later · Apr 19, 2024
  27. Rep. Nancy Mace (R-SC-1)· Later · Apr 23, 2024
  28. Rep. Scott Fitzgerald (R-WI-5)· Later · May 1, 2024
  29. Rep. Don Bacon (R-NE-2)· Later · May 10, 2024
  30. Rep. Kevin Mullin (D-CA-15)· Later · May 14, 2024
  31. Rep. Tony Cárdenas (D-CA-29)· Later · May 21, 2024
  32. Rep. Mike Carey (R-OH-15)· Later · Jun 3, 2024
  33. Rep. Jesús G. "Chuy" García (D-IL-4)· Later · Jun 5, 2024
  34. Rep. Judy Chu (D-CA-28)· Later · Jul 22, 2024
  35. Rep. Lois Frankel (D-FL-22)· Later · Jul 22, 2024
  36. Rep. Hillary J. Scholten (D-MI-3)· Later · Aug 16, 2024
  37. Rep. Jason Crow (D-CO-6)· Later · Aug 23, 2024
  38. Rep. Anthony D'Esposito (R-NY-4)· Later · Aug 23, 2024
  39. Rep. Andrew R. Garbarino (R-NY-2)· Later · Sep 3, 2024
  40. Rep. Josh Harder (D-CA-9)· Later · Sep 10, 2024
  41. Rep. Jerrold Nadler (D-NY-12)· Later · Oct 25, 2024
  42. Rep. Susie Lee (D-NV-3)· Later · Nov 20, 2024
  43. Rep. Claudia Tenney (R-NY-24)· Later · Dec 5, 2024
  44. Rep. Ken Calvert (R-CA-41)· Later · Dec 9, 2024
  45. Rep. Lloyd Doggett (D-TX-37)· Later · Dec 16, 2024
  46. Rep. Nicole Malliotakis (R-NY-11)· Later · Dec 17, 2024
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Animal protection and human-animal relationships
  • Congressional oversight
  • Department of Health and Human Services
  • Drug safety, medical device, and laboratory regulation
  • Food and Drug Administration (FDA)
  • Government information and archives
  • Internet, web applications, social media
  • 1 more
    • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in House

    Document: Introduced in House

    Sources
  2. Latest
    ▸ 2 committee actions · Feb 6, 2024 – Feb 9, 2024
    1. Referred to committee

      Referred to the House Committee on Energy and Commerce.

      Sources
    2. Referred to Health

      Referred to the Subcommittee on Health.

      Sources
  3. Expired

    Introduced → Referred to House Health → No further action before the 118th Congress ended.

Committees

  1. HouseEnergy and CommerceReferred Feb 6, 2024
  2. HouseHealthReferred Feb 9, 2024
    1. Feb 29, 2024 · Hearing

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in House
Titles (2)
  1. FDA Modernization Act 3.0

    Display title, Short title · Introduced in House

  2. To amend the Federal Food, Drug, and Cosmetic Act to establish a process for the qualification of nonclinical testing methods to reduce and replace the use of animals in nonclinical research, improve the predictivity of nonclinical testing methods, and reduce development time for a biological product or other drug, and for other purposes.

    Official title · Introduced in House